Press Release

Monaco, Principality of Monaco. ONA Therapeutics nominated finalist at Third Annual Lyfebulb-Helsinn Cancer Innovation Summit & Award

Lyfebulb and Helsinn Announce 11 Finalists for the Third Annual Lyfebulb-Helsinn Cancer Innovation Summit & Award

MONACO, PRINCIPALITY OF MONACO, AND NEW YORK, NY, USA, January 14, 2020: Lyfebulb, a patient empowerment platform that connects patients with industry to support user-driven innovation toward solutions in chronic disease, and Helsinn, a Swiss pharmaceutical group focused on building quality cancer care, announce the 11 Patient Entrepreneurs chosen as finalists for the Lyfebulb-Helsinn Cancer Innovation Summit & Award to be held on January 30, 2020. The Award recognizes Patient Entrepreneurs demonstrating outstanding innovations which advance solutions in the prevention, management or care of cancer. Valerie Vanhooren, Co-founder and CEO of ONA Therapeutics has been selected as one of the finalists.

Read full press release here:

https://www.helsinn.com/news-and-events/lyfebulb-and-helsinn-announce-11-finalists-for-the-third-annual-lyfebulb-helsinn-cancer-innovation-summit-and-award/